Skip to content

Acute Technical Outcomes of the Talent Abdominal Aortic Aneurysm (AAA) Stent-Graft Versus Cook Zenith Stent-Graft

Acute Technical Outcomes of the Talent AAA Stent -Graft vs. Cook Zenith Stent- Graft: A Case-Control Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00922454
Enrollment
200
Registered
2009-06-17
Start date
2009-06-30
Completion date
2011-06-30
Last updated
2009-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysm

Keywords

patients will be matched based on AAA neck length and neck and iliac angulation

Brief summary

The purpose of this study is to compare acute technical outcomes of the Talent AAA Stent Graft system versus Cook Zenith Endograft at two high volume institutions, Albany Medical Center and St. Peter's Hospital in Albany, NY. The investigators are comparing the two devices as part of the evolution of endovascular repair (EVAR) for AAAs. The Zenith AAA Endovascular Graft received FDA approval on May 23, 2003, the Talent Abdominal Stent Graft System on April 15, 2008.

Interventions

PROCEDUREEndovascular Repair of the abdominal aorta

Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft. EVAR, CTA imaging, 1, 6 12 months post treatment.

DEVICECook Zenith Stent-Graft

Cook Zenith AAA Endovascular Graft

DEVICETalent Stent-Graft

Talent AAA Abdominal Stent Graft System

Sponsors

Center for Vascular Awareness, Albany, New York
Lead SponsorOTHER

Study design

Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* subject with abdominal aortic aneurysm, with or without iliac involvement * iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories

Exclusion criteria

* less than 18 years of age * pregnant or lactating * have contraindications for use of contrast medium or anticoagulation drugs * are patients who have a condition that threatens to infect the graft * are patients with sensitivities or allergies to the device materials

Design outcomes

Primary

MeasureTime frame
Acute technical success, successful exclusion of the aneurysmone year

Countries

United States

Contacts

Primary ContactDeborah Hill, RN
hilld@albanyvascular.com518 45202198
Backup ContactAnita Suchdeve, RN
suchdevea@albanyvascular.com518 452-1263

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026